Analysts See $0.89 EPS for Greif, Inc. (GEF); Ligand Pharmaceuticals (LGND) Sellers Decreased By 3.78% Their Shorts

November 15, 2017 - By wolcottdaily

Ligand Pharmaceuticals (NASDAQ:LGND) had a decrease of 3.78% in short interest. LGND’s SI was 3.57 million shares in November as released by FINRA. Its down 3.78% from 3.71 million shares previously. With 168,500 avg volume, 21 days are for Ligand Pharmaceuticals (NASDAQ:LGND)’s short sellers to cover LGND’s short positions. The SI to Ligand Pharmaceuticals’s float is 17.51%. The stock increased 1.59% or $2.27 during the last trading session, reaching $145.07. About 14 shares traded. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 2.87% since November 15, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Analysts expect Greif, Inc. (NYSE:GEF) to report $0.89 EPS on December, 6.They anticipate $0.24 EPS change or 36.92% from last quarter’s $0.65 EPS. GEF’s profit would be $45.27 million giving it 14.52 P/E if the $0.89 EPS is correct. After having $0.85 EPS previously, Greif, Inc.’s analysts see 4.71% EPS growth. The stock decreased 0.23% or $0.12 during the last trading session, reaching $51.7. About shares traded. Greif, Inc. (NYSE:GEF) has risen 67.37% since November 15, 2016 and is uptrending. It has outperformed by 50.67% the S&P500.

Ligand Pharmaceuticals Incorporated is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has market cap of $3.06 billion. The Firm is involved in the development and licensing of biopharmaceutical assets. It has a 210.3 P/E ratio. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Investors sentiment increased to 1.24 in Q2 2017. Its up 0.06, from 1.18 in 2017Q1. It improved, as 22 investors sold Ligand Pharmaceuticals Inc. shares while 79 reduced holdings. 36 funds opened positions while 89 raised stakes. 22.57 million shares or 0.91% more from 22.37 million shares in 2017Q1 were reported. Pax World Ltd Liability Com holds 1.25% or 182,440 shares. Elk Creek Prns Limited Co invested in 133,782 shares or 1.05% of the stock. Raymond James & Associate stated it has 0% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Ny State Teachers Retirement Systems holds 0.01% or 37,233 shares in its portfolio. Texas-based Employees Retirement Systems Of Texas has invested 0.02% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Advisory Service Ltd Liability owns 0% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 141 shares. Tiaa Cref Inv Ltd Liability invested 0.01% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Arizona State Retirement holds 9,975 shares. Fifth Third Bancorporation holds 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) or 5,097 shares. Principal Fincl Gru Inc invested 0.02% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Pub Employees Retirement Association Of Colorado reported 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Guggenheim Capital Ltd Llc has invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The Virginia-based Virginia Retirement Et Al has invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Friedberg Invest Mgmt owns 4,220 shares. Campbell Newman Asset Mgmt owns 0.05% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 2,494 shares.

Since June 9, 2017, it had 0 buys, and 1 sale for $1.38 million activity. Another trade for 12,000 shares valued at $1.38M was sold by HIGGINS JOHN L.

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ligand Pharmaceuticals had 21 analyst reports since September 3, 2015 according to SRatingsIntel. Deutsche Bank maintained it with “Hold” rating and $103 target in Monday, July 17 report. The firm has “Buy” rating by Roth Capital given on Wednesday, September 30. The firm earned “Buy” rating on Friday, December 18 by TH Capital. On Wednesday, October 5 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by Roth Capital with “Buy” on Friday, December 18. The rating was downgraded by Deutsche Bank on Friday, August 5 to “Sell”. Roth Capital maintained the shares of LGND in report on Friday, March 11 with “Buy” rating. The firm earned “Buy” rating on Monday, November 13 by Roth Capital. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has “Buy” rating given on Monday, September 21 by Roth Capital. The firm has “Overweight” rating by Stephens given on Wednesday, April 13.

Greif, Inc. is a producer of industrial packaging services and products. The company has market cap of $2.63 billion. The Company’s divisions are Rigid Industrial Packaging & Services; Paper Packaging & Services; Flexible Products & Services, and Land Management. It has a 26.38 P/E ratio. The Rigid Industrial Packaging & Services segment is engaged in the production and sale of rigid industrial packaging products, and services, such as container life cycle management, filling, logistics, warehousing and other packaging services.

Investors sentiment decreased to 0.78 in 2017 Q2. Its down 0.24, from 1.02 in 2017Q1. It fall, as 16 investors sold Greif, Inc. shares while 78 reduced holdings. 29 funds opened positions while 44 raised stakes. 22.43 million shares or 4.22% less from 23.42 million shares in 2017Q1 were reported. 3.62M were accumulated by Vanguard Gp. Kansas-based Creative Planning has invested 0% in Greif, Inc. (NYSE:GEF). 6,299 were reported by Cubist Systematic Strategies Limited Liability Company. Northern accumulated 439,303 shares. Ls Advisors Lc owns 0.01% invested in Greif, Inc. (NYSE:GEF) for 2,022 shares. Neuberger Berman Group Inc Limited Liability Corp holds 11,231 shares. Moreover, Sg Americas Secs Llc has 0% invested in Greif, Inc. (NYSE:GEF). 490,263 were accumulated by Voya Inv Mngmt. Prudential holds 0.04% or 462,812 shares in its portfolio. Ubs Asset Mgmt Americas has invested 0% in Greif, Inc. (NYSE:GEF). 17,700 are owned by Hbk Invs Ltd Partnership. Magnetar Financial Ltd Liability Company holds 13,608 shares or 0.01% of its portfolio. Laurion Cap Ltd Partnership stated it has 0% in Greif, Inc. (NYSE:GEF). Virginia Retirement Sys Et Al holds 0.02% or 27,400 shares in its portfolio. Jpmorgan Chase And holds 0% or 196,152 shares in its portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :